Lorenzo Falchi MD; ASH 2025: Bispecific Antibody Epcoritamab Combination Beats Standard of Care for Patients with Relapsed/Refractory Follicular Lymphoma

This episode discusses how the bispecific antibody Epcoritamab, in combination with rituximab and lenalidomide, has outperformed standard treatment for relapsed/refractory follicular lymphoma in the phase three epcore FL-1 trial. Dr. Lorenzo Falchi, an attending physician at Memorial Sloan Kettering, was interviewed at the ASH 2025 Annual Meeting, where these significant findings, including improved ORR and PFS, were presented, demonstrating a substantial reduction in the risk of progression or